Skip to main navigation

Immunocore

Primary Menu

Overview
News & Events
Stock Information
- Stock Quote & Chart
- Analysts Coverage
Corporate Governance
Financials & Filings
- SEC Filings
IR Resources

Primary Menu

Overview
News & Events
Stock Information
- Stock Quote & Chart
- Analysts Coverage
Corporate Governance
Financials & Filings
- SEC Filings
IR Resources

News Releases

Breadcrumb

Home /
Investor Relations /
News & Events /
News Releases

Year

9 February 2021

Immunocore Announces Closing of $312.1 Million Aggregate Financing, Consisting of $297.1 Million Initial Public Offering, Full Exercise of Option to Purchase Additional ADSs and $15.0 Million Concurrent Private Placement

4 February 2021

Immunocore Announces Pricing of Upsized Initial Public Offering

11 January 2021

Immunocore announces closing of $75.0 Million Series C round

3 December 2020

Immunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020

23 November 2020

Immunocore’s tebentafusp demonstrates superior overall survival compared to investigator’s choice in a Phase 3 clinical trial of patients with previously untreated metastatic uveal melanoma

15 October 2020

Immunocore Appoints Nobel Laureate Professor Sir Peter J. Ratcliffe as Non-Executive Director

27 August 2020

Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B

26 May 2020

Immunocore announces dosing of first patient with fourth ImmTAC

6 May 2020

Immunocore appoints Brian Di Donato as Chief Financial Officer and Head of Strategy

4 March 2020

First Site in Global Uveal Melanoma Patient Registry Now Open

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 11 - 20 of 115

Site - Shareholder Tools

Immunocore

Site - Footer Social

About us
Our science
Our therapy areas
For patients

News
Careers
Contact us

Privacy and Social Media Guidelines
Cookies
Payments and Disclosures
Clinical trials

©2021 Immunocore, Ltd. All rights reserved. ImmTAC, ImmTAV, ImmTAB, ImmTAAI and ImmTAX are all registered trademarks of Immunocore, Ltd